Lilly’s SURMOUNT-2 results published in The Lancet show tirzepatide achieved a mean weight reduction of 15.7% at the highest dose (15 mg) in adults with obesity or overweight and type 2 diabetes

Detailed results presented at the American Diabetes Association’s® 83rd Scientific Sessions Lilly has completed tirzepatide’s submission for chronic weight management to the FDA INDIANAPOLIS, June 24, 2023 /PRNewswire/ — Detailed results from SURMOUNT-2, a phase 3 clinical trial…